Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) shares are trading higher Monday after the company announced it entered into a ...

Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals, Inc.

CITIUS ONCOLOGY, INC. CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS FOR THE SIX MONTHS ENDED MARCH 31, 2025 AND 2024 (Unaudited) 2025 2024 Cash Flows From Operating Activities: Net loss ...

RayzeBio, the radiopharmaceutical unit of Bristol Myers Squibb, licensed an experimental drug and diagnostic agent for prostate cancer from Philochem AG for a $350 million upfront payment. Philochem ...

Citius Pharmaceuticals Inc (NASDAQ: CTXR ), the parent company of Citius Oncology, also saw its shares climb by 6.7%. Meanwhile, Cardinal Health’s stock remained flat after the news.

After the close of the world's largest cancer conference (the 2025 American Society of Clinical Oncology annual meeting), ...

Citius Oncology (NASDAQ:CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals (NASDAQ:CTXR), has entered into a distribution services agreement with Cardinal Health (NYSE:CAH). This ...